Commonwealth Equity Services
NGNE icon

Commonwealth Equity Services’s Neurogene NGNE Stock Holding History

Commonwealth Equity Services’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-715
Closed -$237K – 3100
2020
Q2 		$237K Buy
+715
New +$186K ﹤0.01% 2465

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Commonwealth Equity Services's NGNE Position: Q3 2020 in Review

Commonwealth Equity Services sold out of Neurogene (NGNE) in Q3 2020, closing a stake of 715 shares — an estimated $237K sold.

Commonwealth Equity Services first reported a position in NGNE in Q2 2020 and held it in 1 quarter. The position peaked at $237K in Q2 2020. 81 funds tracked by Wall St. Rank hold NGNE as of Q3 2020.

  • Commonwealth Equity Services reported no remaining Neurogene position as of Q3 2020 after selling out during the quarter.
  • Commonwealth Equity Services sold 715 Neurogene shares in Q3 2020, an estimated $237K.
  • Commonwealth Equity Services first reported a position in Neurogene in Q2 2020 and held it in 1 quarter.
  • Commonwealth Equity Services's Neurogene position peaked at $237K in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Neurogene as of Q3 2020.

Based on Commonwealth Equity Services's 13F filing for Q3 2020, filed 5 Nov 2020.